Hormonal

Linaclotide

Also known as: Linzess, Constella

FDA Approved
Share:

Key Facts: Linaclotide

Category
Hormonal
FDA Status
FDA Approved
Clinical Status
FDA Approved - IBS-C and chronic constipation
Administration
Oral capsule on empty stomach
Typical Dose
Limited community data available
Frequency
See research protocols
Duration
Long-term / chronic use
Also Known As
Linzess, Constella

Mechanism of Action

Linaclotide activates guanylate cyclase-C on intestinal epithelium, increasing cGMP which leads to chloride and water secretion into the intestines. Also reduces visceral pain signaling.

Research Summary

Multiple trials showed improvement in bowel movements and abdominal pain in IBS-C. Works within the first week. Also effective for chronic idiopathic constipation.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosing

Community experience

Common Dose

Limited community data available

Range

See research dosing

Frequency

See research protocols

Research Dosing

Scientific studies

FDA-approved dosing

Duration

Long-term / chronic use

Administration

Oral capsule on empty stomach

Timing & Administration

Best Time to Take

Morning or as directed

Follow recommended protocol

Food Recommendation

With or without food

Why This Timing?

Timing may vary based on individual response and goals. Consistency is generally more important than specific timing.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Diarrhea (up to 50%)
  • Abdominal pain
  • Flatulence
  • Fecal incontinence
  • CONTRAINDICATED in children <2 years
  • FDA approved (Linzess)

References

Research This Peptide Further

Frequently Asked Questions

What does Linaclotide do?

A peptide guanylate cyclase-C agonist for IBS-C and chronic constipation. Works locally in the gut with minimal systemic absorption.

How does Linaclotide work?

Linaclotide activates guanylate cyclase-C on intestinal epithelium, increasing cGMP which leads to chloride and water secretion into the intestines. Also reduces visceral pain signaling.

Is Linaclotide FDA approved?

Yes, Linaclotide is FDA approved. FDA Approved - IBS-C and chronic constipation

What are the side effects of Linaclotide?

Reported side effects include: Diarrhea (up to 50%), Abdominal pain, Flatulence, Fecal incontinence, CONTRAINDICATED in children <2 years. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Linaclotide?

Community-reported common dose: Limited community data available (See research protocols). Range: See research dosing. Administration: Oral capsule on empty stomach. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Linaclotide or used in similar applications.

Want updates on Linaclotide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.